A traditional Chinese medicine composition for treating lumbar disc herniation

Abstract

The application provides a traditional Chinese medicine composition for treating lumbar disc herniation, and active ingredients of the traditional Chinese medicine composition are prepared from raw medicinal materials in the following proportions by weight: 17-25 parts of Danshen, 8-15 parts of Sanqi, 8-15 parts of Angelica sinensis, 2-5 parts of scorpion and 1-3 parts of centipede; in the traditional Chinese medicine composition, Danshen, Sanqi, Angelica sinensis, scorpion and centipede are used as active ingredients of raw materials, and the use principle of a monarch, a minister, an assistant and a guide in traditional Chinese medicine is followed; the whole prescription is used together, has the effects of activating blood and benefiting qi, eliminating swelling and relieving pain, and the combined use of the drugs can effectively treat lumbar disc herniation, thereby providing a new idea for treating lumbar disc herniation by using traditional Chinese medicine compounds.

Description

Technical Field

[0001] This invention relates to the field of traditional Chinese medicine technology, and more specifically, to a traditional Chinese medicine composition for treating lumbar disc herniation. Background Technology

[0002] Lumbar disc herniation (LDH) refers to a clinical syndrome caused by degeneration or trauma to the annulus fibrosus of the lumbar intervertebral disc. Under the action of external force, the annulus fibrosus ruptures, and the nucleus pulposus and other intervertebral disc tissues bulge posteriorly or posterolaterally, irritating or compressing the spinal nerves or cauda equina, causing low back pain, lower limb pain, or bowel and bladder dysfunction, or even significant neurological dysfunction. It is a common and frequently occurring disease in orthopedics, which has a significant impact on the patient's health and daily life. Therefore, clarifying relevant treatment plans and measures to treat this disease has extremely important clinical significance.

[0003] Traditional Chinese medicine does not have the concept of LDH, but based on its pathogenesis and symptoms, it can be categorized under "low back pain" and "bi syndrome." The *Jingyue Quanshu* (Complete Works of Jingyue) states regarding low back pain: "Those who suffer from low back pain due to falls or injuries have injuries to the tendons and bones, causing blood stasis." This records low back pain caused by blood stasis. Sustained exertion on the lower back, overexertion, prolonged poor posture, falls or injuries to the lower back, or prolonged illness affecting the collaterals can damage the tendons and vessels of the lower back, leading to impaired blood circulation and blood stasis in the lower back. Regardless of whether it is due to external pathogens such as cold-dampness or damp-heat, or deficiency of liver and kidney essence and blood, the pathogenesis of blood stasis obstructing the meridians of the lower back is consistently present throughout the course of LDH. Blood stasis is both a pathological product and can further hinder the distribution of qi, blood, and body fluids, forming a vicious cycle of "blood stasis obstruction - pain due to obstruction."

[0004] Currently, there are increasingly more clinical treatment methods for lumbar disc herniation, but they generally fall into three categories: surgical treatment, interventional treatment, and conservative treatment. Surgical treatment may cause varying degrees of damage to the lumbar intervertebral discs, disrupting spinal stability and physiological balance; therefore, its indications must be strictly adhered to. Most patients can achieve good results or even a cure through conservative treatment, making it the preferred method for most patients with lumbar disc herniation. This includes oral medications for dehydration and analgesia, and physical therapy. However, long-term use of nonsteroidal anti-inflammatory drugs (NSAIDs) can cause severe gastrointestinal adverse reactions, and the effects of physical therapy are relatively short-lived. These factors contribute to the recurrence of LDH, making it a persistent and difficult-to-cure condition, placing a heavy burden on patients' finances and daily lives.

[0005] Traditional Chinese medicine (TCM) treatment for lumbar disc herniation is characterized by minimal pain, few complications, easy patient acceptance, and definite efficacy. However, current TCM formulas for treating lumbar disc herniation struggle to simultaneously address both "unblocking the meridians and relieving pain" and "nourishing blood and strengthening the body's resistance." Existing TCM formulas for lumbar disc herniation mainly consist of insect-based and herbal formulas. Insect-based formulas lack blood-nourishing and body-strengthening components, and long-term use can easily deplete qi and blood. Herbal formulas lack sufficient meridian-unblocking power and have limited efficacy against stubborn nerve compression. Furthermore, traditional formulas often focus on dispelling wind and dampness and tonifying the liver and kidneys, which is insufficient for clearing and unblocking the meridians in cases of "meridian obstruction" type LDH. Summary of the Invention

[0006] Based on the aforementioned technical problems in the existing technology, the purpose of this invention is to provide a traditional Chinese medicine composition for treating lumbar disc herniation. This composition has the effects of promoting blood circulation, invigorating qi, reducing swelling and relieving pain, and can effectively treat lumbar disc herniation, providing a new approach for the treatment of lumbar disc herniation with traditional Chinese medicine compound prescriptions.

[0007] To achieve the above objectives, the technical solution of the present invention is as follows:

[0008] A traditional Chinese medicine composition for treating lumbar disc herniation, wherein the active ingredients are prepared from the following raw materials in parts by weight:

[0009] Salvia miltiorrhiza 17-25 parts, Panax notoginseng 8-15 parts, Angelica sinensis 8-15 parts, scorpion 2-5 parts, and centipede 1-3 parts.

[0010] In some embodiments, the active ingredient of the traditional Chinese medicine composition is prepared from the following parts by weight of raw materials:

[0011] Salvia miltiorrhiza 20 parts, Panax notoginseng 10 parts, Angelica sinensis 10 parts, scorpion 3 parts, and centipede 2 parts.

[0012] In some embodiments, the traditional Chinese medicine composition is a preparation made from the active ingredients of the raw material powder, water or organic solvent extract of the raw material in the specified weight proportions, plus pharmaceutically acceptable excipients.

[0013] In some embodiments, the traditional Chinese medicine composition is in the form of granules, pills, tablets, decoctions, or hard capsules.

[0014] The pharmacological effects of this invention are as follows:

[0015] Salvia miltiorrhiza: Bitter in taste, slightly cold in nature; enters the heart and liver meridians. Functions: Invigorates blood circulation and removes blood stasis, regulates menstruation and relieves pain, clears the heart and eliminates irritability, cools the blood and reduces swelling. Used for chest pain, abdominal and hypochondriac pain, abdominal masses, painful arthralgia, insomnia, irregular menstruation, dysmenorrhea, amenorrhea, sores and swelling, etc.

[0016] Panax notoginseng: Sweet and slightly bitter in taste, warm in nature; enters the liver and stomach meridians. Functions: Disperses blood stasis and stops bleeding, reduces swelling and relieves pain. Used for hemoptysis, hematemesis, epistaxis, hematochezia, metrorrhagia, traumatic bleeding, chest and abdominal pain, and swelling and pain from falls.

[0017] Angelica sinensis: Sweet and pungent in taste, warm in nature; enters the liver, heart, and spleen meridians. Functions: Nourishes and invigorates blood, regulates menstruation and relieves pain, moistens the intestines and promotes bowel movement. Used for blood deficiency and chlorosis, dizziness and palpitations, irregular menstruation, amenorrhea and dysmenorrhea, abdominal pain due to deficiency and cold, rheumatic pain, traumatic injuries, carbuncles and sores, and constipation due to intestinal dryness.

[0018] Scorpion: pungent in taste, neutral in nature, and poisonous; enters the liver meridian. Functions: calms wind and relieves spasms, attacks toxins and dissipates nodules, unblocks meridians and relieves pain. Used for infantile convulsions, epilepsy, stroke, hemiplegia, tetanus, stubborn rheumatism, migraine, etc.

[0019] Centipede: pungent in taste, warm in nature, and poisonous; enters the liver meridian. Functions: calms wind and relieves spasms, unblocks meridians and relieves pain, attacks toxins and dissipates nodules. Used for internal liver wind, spasms and convulsions, rheumatic pain, migraine, carbuncles, and boils.

[0020] Compared with the prior art, the beneficial effects of the present invention are as follows:

[0021] The traditional Chinese medicine composition provided in this application uses Salvia miltiorrhiza, Panax notoginseng, Angelica sinensis, scorpion, and centipede as active ingredients. It follows the principle of "principal, assistant, adjuvant, and guide" in traditional Chinese medicine. Centipede is good at penetrating and can penetrate deep into the meridians to relieve muscle spasms. Scorpion is good at attacking toxins, dispersing nodules, and relieving pain by clearing the meridians. Panax notoginseng can not only promote blood circulation and remove blood stasis, but also stop bleeding and relieve pain. It is especially good at treating blood stasis caused by external injuries or chronic diseases. Angelica sinensis nourishes and promotes blood circulation, and can also warm the meridians and clear the channels. It can relieve numbness in the waist and legs caused by blood deficiency and blood stasis. Salvia miltiorrhiza promotes blood circulation, removes blood stasis, cools blood and reduces swelling. When combined with Angelica sinensis, it enhances the blood circulation and can prevent the transformation of blood stasis into heat. The two work together to improve the circulation of qi and blood. The entire formula combines insect-based and herbal medicines: centipede and scorpion have a strong effect in clearing the meridians and relieving pain, while Panax notoginseng, Angelica sinensis, and Salvia miltiorrhiza invigorate blood and nourish blood, avoiding the drawbacks of insect-based medicines that deplete qi and blood; it combines attack and tonification: Panax notoginseng removes blood stasis and promotes new blood production, while Angelica sinensis nourishes blood and strengthens the body, making it suitable for patients with qi and blood stagnation and deficiency; the entire formula closely follows the pathogenesis of "qi and blood stagnation", achieving the effect of "no pain when there is free flow" by invigorating blood and clearing the meridians, which is in line with the principle of "using free flow as the key" in the treatment of lumbar disc herniation in traditional Chinese medicine, thus achieving effective treatment of lumbar disc herniation. Attached Figure Description

[0022] Figure 1 HE and Masson staining results for different groups of rats. Detailed Implementation

[0023] Numerous specific details are set forth in the following description to provide a full understanding of the invention. However, the invention can be practiced in many other ways than those described herein, and similar modifications can be made by those skilled in the art without departing from the spirit of the invention. Therefore, the invention is not limited to the specific embodiments disclosed below.

[0024] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention pertains. The terminology used herein in the description of the invention is for the purpose of describing particular embodiments only and is not intended to be limiting of the invention.

[0025] Example 1

[0026] A traditional Chinese medicine composition for treating lumbar disc herniation, the preparation of which includes the following steps:

[0027] Take 2kg of centipede, 3kg of scorpion, 10kg of Panax notoginseng, 10kg of Angelica sinensis, and 20kg of Salvia miltiorrhiza, combine them, add water and decoct twice. For the first decoction, add 10 times the amount of water, soak for 0.5h, and decoct for 1h (keeping it at a gentle boil for 1h). For the second decoction, add 8 times the amount of water and decoct for 1h (keeping it at a gentle boil for 1h). Combine the decoctions, filter, concentrate the filtrate to a relative density of 1.15 (80℃, measured hot), cool to room temperature, add volatile oil, mix well, and obtain a thick paste.

[0028] Take 5 kg of white sugar powder (passed through an 80-mesh sieve), add it to the thick paste, mix well, granulate, pass through a 16-mesh sieve, place the sieved granules at 80℃ for 4 hours, granulate again (pass through a 16-mesh sieve), and obtain granules. Pack the granules into aluminum-plastic composite film bags, each bag containing 9g, to obtain granules (Wuhu Tongbi Formula Granules).

[0029] Pharmacological experiments

[0030] To further evaluate the efficacy of the traditional Chinese medicine composition of this application, pharmacological experiments were conducted on the drug of Example 1, with celecoxib tablets used as a control drug, as detailed below:

[0031] I. Animal Experiments

[0032] 1. Materials

[0033] 1.1 Animals

[0034] Thirty adult healthy male SD rats, specific pathogen-free (SPF) grade, weighing (200±20) g.

[0035] 1.2 Drugs and Reagents

[0036] The raw material of the traditional Chinese medicine composition in Example 1 is ultrafine particle;

[0037] Celecoxib Capsules (Pfizer Pharmaceuticals Co., Ltd., National Drug Approval Number H20140106);

[0038] Interleukin-1β (IL-1β) and tumor necrosis factor-α (TNF-α) enzyme-linked immunosorbent assay (ELISA) kit (Beyotime Biotechnology Co., Ltd., batch numbers P1303 and PT516 respectively).

[0039] Substance P (SP) and Neuropeptide Y (NPY) ELISA kits (Shanghai Sangon Biotech, batch numbers D751030-0096 and D731180-0096 respectively).

[0040] HE staining solution kit (Pinofi Biotechnology Co., Ltd., S191003); Masson staining solution kit (Pinofi Biotechnology Co., Ltd., S191006).

[0041] 1.3 Experimental Apparatus

[0042] Pathological sectioning machine (LEICA GmbH, Germany); DM3000 optical microscope (Leica GmbH, Germany)

[0043] 2 Methods

[0044] 2.1 Drug Preparation

[0045] 2g of centipede, 3g of scorpion, 10g of Panax notoginseng, 10g of Angelica sinensis, and 20g of Salvia miltiorrhiza were mixed with purified water and suspended with 0.5% CMC-Na to prepare a powder containing 0.45g of raw herbs per mL. -1 The extract was used to obtain the Wuhu Tongbi formula.

[0046] Take celecoxib capsules, remove the capsule shells, take the powder, add purified water and mix well to prepare a solution containing celecoxib at a concentration of 2.4 mg / mL. -1 The suspension was used to obtain celecoxib for group use (prepared before use).

[0047] 2.2 Model Establishment

[0048] After anesthetizing rats with 1% sodium pentobarbital (30 mg / kg) via intraperitoneal injection, they were fixed in a prone position. The surgical site was shaved, prepared, disinfected, and draped. A posterior midline incision of about 2.5 cm was made at the midpoint of the line connecting the bilateral iliac spines. After the paravertebral muscles were cleaned, the right L5 lamina, inferior articular process, and superior articular process of L6 were removed with lamina cleaving forceps to expose the right L5 nerve root. The tail was then longitudinally incised, and two intervertebral disc nuclei (about 5 mg) were removed and placed on the surface of the L5 nerve root, taking care not to cause significant compression. The incision was closed by suturing layer by layer. Postoperatively, penicillin (200,000 U / day) was administered intramuscularly for 3 consecutive days to prevent infection.

[0049] 2.3 Animal grouping, drug administration, and sample collection

[0050] Thirty healthy adult SD rats were randomly divided into three groups: a model group, a celecoxib group, and a Wuhu Tongbi formula group, with ten rats in each group (half male and half female). Based on the drug dosage conversion between human and rat body surface area, the celecoxib group was administered 24 mg / kg. -1 Gavage once daily; Five Tigers Relief Formula group administered 0.45g / kg. -1 The patients were given gavage once a day; the model group was given an equal volume of purified water.

[0051] Two weeks after intervention, each group underwent intraperitoneal anesthesia, and the right L5 nerve root, including the dorsal root ganglion, was harvested. Half of the roots were fixed in 4% paraformaldehyde solution, and the other half were stored in EP tubes at -80℃ for later use.

[0052] 2.4 Indicator Testing

[0053] Before and after the intervention, the motor function scores of the rats' right hind limb were observed: normal gait was 0 points, mild lameness was 1 point, weakness of the hind limb with moderate lameness was 2 points, and mild paralysis and obvious lameness of the hind limb were 3 points.

[0054] The levels of IL-1β, TNF-α, SP, and NPY in nerve roots were detected by ELISA.

[0055] The nerve root tissue was dehydrated, cleared, embedded in paraffin, sectioned, and dewaxed. It was then stained with HE and Masson staining, and the pathological changes of the nerve root were observed under a microscope.

[0056] 2.5 Data Processing

[0057] SPSS 22.0 statistical software was used for statistical analysis of the data. Data are expressed as mean ± standard deviation ( ). () indicates the significance of the difference. One-way ANOVA was used for comparisons between the two groups. A p-value < 0.05 was considered statistically significant.

[0058] 3 Results

[0059] The effects of drug intervention are shown in Table 1. Compared with the model group, the motor function scores of the Wuhutongbi group and the celecoxib group were reduced (P<0.05). After corresponding drug treatment, the contents of IL-1β, TNF-α, SP, and NPY in the nerve roots of the Wuhutongbi group and the celecoxib group were significantly reduced (P<0.05).

[0060] like Figure 1 As shown, HE and Masson staining results indicated that the model group had significant edema in the nerve roots, disordered cell arrangement, unclear nuclear membrane, vacuolation in the cytoplasm, and necrosis of the myelin sheath in some nerve fibers; while the pathological changes in the spinal nerve roots of rats in the Wuhutongbi group and celecoxib group were significantly reduced compared with those in the model group.

[0061] Table 1 Comparison of motor function scores and inflammatory markers among different groups of rats ( (n=10)

[0062]

[0063] Note: Compared with the model group, * P < 0.05.

[0064] II. Clinical Trials

[0065] The clinical efficacy of the Wuhu Tongbi formula granules prepared in Example 1 in treating lumbar disc herniation with blood stasis and obstruction of collaterals is as follows:

[0066] 1. Materials and Methods

[0067] 1.1 Clinical Data

[0068] The study included 100 patients with lumbar disc herniation and blood stasis syndrome who met the inclusion criteria and were treated at the orthopedic outpatient clinic of Hunan Provincial Hospital of Integrated Traditional Chinese and Western Medicine from June 2024 to January 2025. These patients were randomly divided into two groups of 50 each. The observation group consisted of 34 males and 16 females, aged 22–47 years, with a mean age of (32.0±5.29) years. The control group consisted of 29 males and 21 females, aged 21–49 years, with a mean age of (32.0±4.24) years.

[0069] There were no statistically significant differences in the general characteristics of the two groups of patients (P>0.05), indicating they were comparable.

[0070] 1.2 Inclusion and Exclusion Criteria

[0071] Inclusion criteria: (1) Those who meet the diagnostic criteria for lumbar disc herniation with blood stasis and obstruction of collaterals. (2) Those without drug allergy symptoms. (3) Those with complete clinical data.

[0072] Exclusion criteria: (1) Those in the acute exacerbation stage; (2) Those with obvious cauda equina compression symptoms requiring surgery; (3) Those with other related bone and joint diseases, including lumbar spondylolisthesis, lumbar spinal stenosis, lumbar tuberculosis, spinal cord tumors, or rheumatoid arthritis, ankylosing spondylitis, etc.; (4) Those with serious primary diseases of the hematopoietic system, cardiovascular system, endocrine system, tumors, and mental illness; pregnant or lactating women; (5) Those who are deemed unsuitable for inclusion by the researchers, or those who are participating in other clinical trials; (6) Those who are allergic to the traditional Chinese medicine used in this study.

[0073] 1.3 Methods

[0074] The control group was treated with celecoxib capsules (CSPC Ouyi Pharmaceutical Co., Ltd.). Oral administration: Adults take 200 mg once daily, one tablet, swallowed with water 30 minutes after a meal. The course of treatment is 2 weeks.

[0075] The observation group was treated with the granules prepared in Example 1 of this invention, orally, one dose daily, taken with warm water 30 minutes after meals. The course of treatment was 2 weeks.

[0076] 1.4 Observation Indicators

[0077] Effectiveness indicators:

[0078] (1) Statistical analysis of TCM syndrome scores before and after treatment in the two groups. The higher the score, the more severe the symptoms.

[0079] (2) The efficacy evaluation criteria for LDH were formulated based on the "Standards for Diagnosis and Efficacy Evaluation of Diseases and Syndromes in Traditional Chinese Medicine". Cured: Lower back pain, lower limb symptoms, and various daily living functions have completely returned to normal; the patient can raise their legs straight up to 70° or higher while lying flat. Significantly Effective: Lower back pain is reduced, radiating pain in the lower limbs disappears, and lumbar mobility is close to normal; symptoms persist even after prolonged or high-intensity work. Effective: Clinical symptoms are reduced, and the patient can walk, but work and life are still affected to some extent. Ineffective: Symptoms do not improve, or even worsen. Total effective rate (%) = (Number of cured cases + Number of significantly effective cases + Number of effective cases) ÷ Total number of cases × 100%.

[0080] (3) The Japanese Orthopaedic Association (JOA) assessment scores were statistically analyzed before and after treatment in both groups. The JOA score includes four aspects: subjective symptoms, clinical signs, daily living activities and bladder function, ranging from 0 to 29 points. The lower the score, the more severe the functional impairment.

[0081] (4) Statistical analysis of ODI scores before and after treatment in the two groups: Oswestry Disability Index. The ODI questionnaire focuses on self-care ability (such as sitting, standing and walking), with a total score of 50 points. The higher the score, the more severe the limitation of lumbar spine function.

[0082] (5) The pain VAS scores of the two groups before and after treatment were statistically analyzed. The Visual Analogue Scale / Score (VAS) was used for evaluation, with a score range of 0 to 10. 0 points indicates no pain and no pain sensation; 1 to 3 points indicate mild pain that does not affect work or life; 4 to 6 points indicate moderate pain that affects work but not life; and 7 to 10 points indicate severe pain that is intense and affects work and life.

[0083] 1.5 Statistical Analysis

[0084] Data were analyzed using SPSS 25.0, with quantitative data presented as follows: The comparison between groups was performed using the t-test. Count data were expressed as number of cases or percentages, and the chi-square test was used. ２ Test. P < 0.05 indicates that the difference is statistically significant.

[0085] 2 Results

[0086] 2.1 Comparison of TCM syndrome scores before and after treatment in the two groups

[0087] As shown in Table 2, there was no statistically significant difference in TCM syndrome scores between the two groups before treatment (P>0.05). After treatment, the TCM syndrome scores of both groups decreased, and the TCM syndrome score of the observation group was significantly lower than that of the control group (P<0.05).

[0088] Table 2 Comparison of TCM syndrome scores between the two groups of patients ( ,point)

[0089]

[0090] 2.2 Comparison of overall effectiveness between the two groups

[0091] As shown in Table 3, the total effective rate of the observation group was higher than that of the control group (P<0.05).

[0092] Table 3 Comparison of treatment efficacy between the two groups of patients (cases)

[0093]

[0094] 2.3 Comparison of lumbar spine JOA scores before and after treatment in the two groups

[0095] As shown in Table 4, there was no statistically significant difference in the lumbar spine JOA scores between the two groups before treatment (P>0.05). After treatment, the lumbar spine JOA scores of both groups increased, and the TCM syndrome score of the observation group was significantly higher than that of the control group (P<0.05).

[0096] Table 4 Comparison of lumbar spine JOA scores between the two groups of patients ( ,point)

[0097]

[0098] 2.4 Comparison of ODI scores before and after treatment in the two groups

[0099] As shown in Table 5, there was no statistically significant difference in ODI scores between the two groups before treatment (P>0.05). After treatment, the ODI scores of both groups decreased, and the ODI score of the observation group was significantly lower than that of the control group (P<0.05).

[0100] Table 5 Comparison of ODI scores between the two groups of patients ( ,point)

[0101]

[0102] 2.5 Comparison of VAS pain scores before and after treatment in the two groups

[0103] As shown in Table 6, there was no statistically significant difference in pain VAS scores between the control group and the observation group before treatment (P>0.05), but the pain VAS score of the observation group was lower than that of the control group after treatment (P<0.05).

[0104] Table 6 Comparison of VAS pain scores between the two groups of patients ( ,point)

[0105]

[0106] 2.6 Security Comparison

[0107] Two patients in the control group experienced mild stomach discomfort after taking the medication, which improved after rest. No adverse events occurred in the observation group, indicating that the traditional Chinese medicine composition of the present invention has good therapeutic safety.

[0108] The technical features of the above embodiments can be combined in any way. For the sake of brevity, not all possible combinations of the technical features in the above embodiments are described. However, as long as there is no contradiction in the combination of these technical features, they should be considered to be within the scope of this specification.

[0109] The embodiments described above are merely illustrative of several implementations of the present invention, and while the descriptions are relatively specific and detailed, they should not be construed as limiting the scope of the invention patent. It should be noted that those skilled in the art can make various modifications and improvements without departing from the concept of the present invention, and these all fall within the protection scope of the present invention. Therefore, the protection scope of this invention patent should be determined by the appended claims.

Claims

1. A traditional Chinese medicine composition for treating lumbar disc herniation, characterized in that, Its active ingredient is prepared from the following parts by weight of active pharmaceutical ingredient: Salvia miltiorrhiza 17-25 parts, Panax notoginseng 8-15 parts, Angelica sinensis 8-15 parts, scorpion 2-5 parts, and centipede 1-3 parts.

2. The traditional Chinese medicine composition for treating lumbar disc herniation according to claim 1, characterized in that, Its active ingredient is prepared from the following parts by weight of active pharmaceutical ingredient: Salvia miltiorrhiza 20 parts, Panax notoginseng 10 parts, Angelica sinensis 10 parts, scorpion 3 parts, and centipede 2 parts.

3. The traditional Chinese medicine composition for treating lumbar disc herniation according to claim 1, characterized in that, The traditional Chinese medicine composition is a preparation made by adding pharmaceutically acceptable excipients to the active ingredients of the raw material powder, water or organic solvent extract of the raw material in the specified weight proportions.

4. The traditional Chinese medicine composition for treating lumbar disc herniation according to claim 1, characterized in that, The traditional Chinese medicine composition is in the form of granules, pills, tablets, decoctions, or hard capsules.

Images